UK markets close in 51 minutes
  • FTSE 100

    7,023.88
    -129.55 (-1.81%)
     
  • FTSE 250

    22,299.49
    -235.65 (-1.05%)
     
  • AIM

    1,230.61
    -10.76 (-0.87%)
     
  • GBP/EUR

    1.1641
    -0.0048 (-0.41%)
     
  • GBP/USD

    1.3825
    -0.0099 (-0.71%)
     
  • BTC-GBP

    26,648.09
    -1,584.43 (-5.61%)
     
  • CMC Crypto 200

    911.23
    -28.72 (-3.06%)
     
  • S&P 500

    4,187.18
    -34.68 (-0.82%)
     
  • DOW

    33,392.73
    -430.72 (-1.27%)
     
  • CRUDE OIL

    72.02
    +0.98 (+1.38%)
     
  • GOLD FUTURES

    1,773.40
    -1.40 (-0.08%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.68 (+0.85%)
     
  • DAX

    15,441.05
    -286.62 (-1.82%)
     
  • CAC 40

    6,566.29
    -99.97 (-1.50%)
     

APONTIS PHARMA AG: Notification on the implementation of stabilization measures

  • Oops!
    Something went wrong.
    Please try again later.
·9-min read
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous
10.06.2021 / 21:20
The issuer is solely responsible for the content of this announcement.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

10 June 2021

APONTIS PHARMA AG

Disclosure in accordance with Article 5 para. 4 lit. (b) and para. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("Market Abuse Regulation") of 16 April 2014 and in accordance with Article 6 para. 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 on the implementation of stabilisation measures

Following the pre-stabilisation announcement dated 29 April 2021, the stabilisation manager mentioned below has informed APONTIS PHARMA AG, Monheim am Rhein, Germany, (contact person: Sven Pauly; Telefon: +49 2173 89 55 4900) that stabilisations (within the meaning of Article 3 para. 2 lit. (d) of the Market Abuse Regulation) have taken place with respect to the offer of the following securities as indicated below:

The Securities:

Issuer:

APONTIS PHARMA AG

Guarantor
(if applicable):

n/a

Aggregate nominal amount of the offer
(excluding over-allotment option):

4,600,000

Description:

Ordinary shares with no par value
ISIN DE000A3CMGM5

Offer price:

EUR 19.00

 

Stabilisation:

Stabilisation manager:

Hauck & Aufhäuser Privatbankiers
Aktiengesellschaft

Existence, maximum size of
the over-allotment option:

690,000 ordinary shares with no par value

Stabilisation marketplace:

Frankfurt Stock Exchange, Xetra (XETR)

 

Stabilisations:

Trade date and time

Purchase (P)/ Sale (S)

Nominal value
(pieces)

Execution
price (0.0000)

Currency code
(ISO 4217)

Market place MIC
(ISO 10386)

04.06.2021
09:36:49

P

290

17.1500

EUR

XETR

04.06.2021
09:36:49

P

10

17.3000

EUR

XETR

04.06.2021
09:58:04

P

6

17.3000

EUR

XETR

04.06.2021
09:58:04

P

294

17.2500

EUR

XETR

04.06.2021
10:29:44

P

345

17.2500

EUR

XETR

04.06.2021
10:29:44

P

5

17.3000

EUR

XETR

04.06.2021
10:59:34

P

1

17.4500

EUR

XETR

04.06.2021
10:59:34

P

47

17.5000

EUR

XETR

04.06.2021
10:59:34

P

419

17.3000

EUR

XETR

04.06.2021
10:59:34

P

283

17.3500

EUR

XETR

04.06.2021
12:14:43

P

400

17.3000

EUR

XETR

04.06.2021
12:15:00

P

435

17.4500

EUR

XETR

04.06.2021
12:15:00

P

15

17.5000

EUR

XETR

04.06.2021
12:20:09

P

804

17.5000

EUR

XETR

04.06.2021
12:20:09

P

518

17.7000

EUR

XETR

04.06.2021
12:20:09

P

228

17.6000

EUR

XETR

04.06.2021
12:20:37

P

950

17.7000

EUR

XETR

04.06.2021
12:20:58

P

450

17.7000

EUR

XETR

04.06.2021
12:23:36

P

400

17.2500

EUR

XETR

04.06.2021
12:26:40

P

978

17.2500

EUR

XETR

04.06.2021
12:28:57

P

1,122

17.5000

EUR

XETR

04.06.2021
12:34:38

P

280

17.5000

EUR

XETR

04.06.2021
12:36:47

P

1,820

17.7000

EUR

XETR

04.06.2021
12:44:34

P

482

17.6000

EUR

XETR

04.06.2021
12:46:51

P

718

17.5500

EUR

XETR

04.06.2021
13:35:12

P

427

17.4500

EUR

XETR

04.06.2021
13:35:12

P

303

17.6000

EUR

XETR

04.06.2021
13:35:12

P

438

17.3000

EUR

XETR

04.06.2021
13:35:12

P

215

17.5000

EUR

XETR

04.06.2021
13:37:26

P

17

17.2500

EUR

XETR

04.06.2021
13:40:01

P

600

17.3000

EUR

XETR

04.06.2021
13:42:58

P

700

17.3000

EUR

XETR

04.06.2021
14:17:11

P

300

17.3000

EUR

XETR

04.06.2021
14:17:11

P

246

17.4000

EUR

XETR

04.06.2021
14:17:11

P

439

17.2500

EUR

XETR

04.06.2021
14:17:11

P

399

17.2000

EUR

XETR

04.06.2021
14:19:16

P

116

17.1500

EUR

XETR

04.06.2021
14:33:55

P

300

17.4000

EUR

XETR

04.06.2021
14:34:04

P

17

17.5000

EUR

XETR

04.06.2021
14:34:04

P

283

17.4500

EUR

XETR

04.06.2021
15:22:49

P

3,100

17.5000

EUR

XETR

04.06.2021
16:36:10

P

800

17.5000

EUR

XETR

04.06.2021
17:36:01

P

8,000

17.6000

EUR

XETR

04.06.2021
17:36:01

P

5,000

17.6000

EUR

XETR

04.06.2021
17:36:01

P

5,000

17.6000

EUR

XETR

04.06.2021
17:36:01

P

10,000

17.6000

EUR

XETR

07.06.2021
16:33:16

P

3

17.9000

EUR

XETR

07.06.2021
16:33:16

P

286

17.8500

EUR

XETR

07.06.2021
16:33:16

P

81

18.0000

EUR

XETR

07.06.2021
16:33:16

P

400

17.9500

EUR

XETR

07.06.2021
16:33:16

P

327

17.7000

EUR

XETR

07.06.2021
16:33:16

P

3

17.8000

EUR

XETR

07.06.2021
17:36:09

P

3,000

18.0000

EUR

XETR

07.06.2021
17:36:09

P

10,000

18.0000

EUR

XETR

08.06.2021
09:02:07

P

500

18.0000

EUR

XETR

08.06.2021
09:02:07

P

1,500

18.0000

EUR

XETR

08.06.2021
10:08:03

P

78

17.8500

EUR

XETR

08.06.2021
10:08:03

P

522

17.8000

EUR

XETR

08.06.2021
11:48:08

P

442

17.8500

EUR

XETR

08.06.2021
11:48:08

P

413

17.6500

EUR

XETR

08.06.2021
11:48:08

P

645

17.6000

EUR

XETR

08.06.2021
11:48:41

P

209

17.8500

EUR

XETR

08.06.2021
11:48:41

P

691

17.6000

EUR

XETR

08.06.2021
17:18:41

P

29

17.9000

EUR

XETR

08.06.2021
17:18:41

P

1,171

17.8500

EUR

XETR

08.06.2021
17:30:10

P

200

17.8000

EUR

XETR

08.06.2021
17:30:37

P

800

17.8000

EUR

XETR

08.06.2021
17:30:37

P

285

17.8500

EUR

XETR

08.06.2021
17:30:37

P

115

17.9000

EUR

XETR

08.06.2021
17:36:09

P

10,000

17.9500

EUR

XETR

08.06.2021
17:36:09

P

20,000

17.9500

EUR

XETR

08.06.2021
17:36:09

P

20,000

17.9500

EUR

XETR

08.06.2021
17:36:09

P

20,000

17.9500

EUR

XETR

08.06.2021
17:36:09

P

1,000

17.9500

EUR

XETR

08.06.2021
17:36:09

P

10,000

17.9500

EUR

XETR

10.06.2021
10:36:50

P

801

17.6500

EUR

XETR

10.06.2021
10:36:50

P

263

17.7000

EUR

XETR

10.06.2021
12:42:42

P

33

17.8000

EUR

XETR

10.06.2021
12:42:42

P

781

17.8500

EUR

XETR

10.06.2021
12:45:37

P

10

17.8000

EUR

XETR

10.06.2021
12:45:37

P

956

17.8500

EUR

XETR

10.06.2021
12:45:37

P

961

17.9000

EUR

XETR

10.06.2021
12:45:37

P

156

17.9500

EUR

XETR

10.06.2021
13:14:37

P

353

17.9500

EUR

XETR

10.06.2021
13:14:37

P

26

18.0000

EUR

XETR

10.06.2021
14:28:37

P

500

17.7500

EUR

XETR

10.06.2021
14:28:37

P

344

17.9000

EUR

XETR

10.06.2021
14:28:37

P

24

17.9500

EUR

XETR

10.06.2021
17:36:25

P

25,000

18.2000

EUR

XETR

 

Sum

Aggregated
volume
(pieces)

Weighted price

Currency code
(ISO 4217)

 

180,908

17.8708

EUR

 

IMPORTANT NOTICE

These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold.


10.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

APONTIS PHARMA AG

Alfred-Nobel-Str. 10

40789 Monheim

Germany

E-mail:

info@apontis-pharma.de

Internet:

https://apontis-pharma.de/

ISIN:

DE000A3CMGM5

WKN:

A3CMGM

Listed:

Regulated Unofficial Market in Frankfurt (Scale)

EQS News ID:

1206816


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting